78 results about "Alcohol dependence" patented technology

Gastric retentive dosage forms for sustained release of acamprosate are described which may allow once- or twice-daily dosing for both acute and long-term treatment of a disorder including alcohol dependence, tinnitus, sleep apnea, Parkinson's disease, levodopa-induced dyskinesias in Parkinson's disease, Alzheimer's disease, Huntington's disease, Amyotrophic lateral sclerosis, Cortical spreading depression, migraine, schizophrenia, anxiety, tardive dyskinesia, spasticity, multiple sclerosis, various types pain, or binge eating. Methods of treatment using the dosage forms and methods of making the dosage forms are also described.

The invention discloses a make method for an edible flos puerariae de-alcoholic fruitcake, which comprises the following raw materials: 3kg of flos puerariae, 1.5kg of hovenia dulcis thumb, 5kg of rhizoma imperatae, 5kg of rhizoma phragmitis, 3kg of mung bean powder, 2kg of Poria cocos, 3kg of root of kudzu vine, 2kg of fructus galangae, 3kg of phaseolus calcaratus, 3kg of phaseolus calcaratus flower, 1.5kg of ginger, 1.5kg of galangal, 1.5kg of liquorice, 2kg of smoked plum, 3kg of olive, 3kg of mulberry, 30kg of molasses syrup, 10kg of high fructose corn syrup, 13kg of glucose, 23kg of granulated sugar, 1.5kg of pectin, 0.7kg of malic acid, 2.5kg of persimmon frost, 3kg of pericarpium citri reticulatae, 3kg of pericarpium citri reticulatae viride, 10g of peppermint oil and 120g of menthol, wherein the glucose is divided into two parts, wherein one part is 8kg, and the other part is 5kg; and the malic acid is divided into two equal parts. The edible flos puerariae de-alcoholic fruitcake improves a bad habit that strong tea is used for preventing alcoholism and sobering up, so that the kidney is prevented from being damaged. After a user drinks wine, the user is free from the wine smell so as to improve a wine drinking atmosphere. As the edible flos puerariae de-alcoholic fruitcake is eaten usually, the edible flos puerariae de-alcoholic fruitcake has an improving action on people with alcoholic liver, fatty liver and alcohol dependence. The edible flos puerariae de-alcoholic fruitcake has the advantages of high power concentration, small volume and concentrated functions, is convenient to carry and is convenient to eat.

The present invention provides novel compositions comprising a combination of a 5-HT3 receptor antagonist and a selective dopamine D2 receptor antagonist for the treatment of obsessive, impulsive and compulsive behavioral activities and other dopamine pathway-associated disorders or conditions. Preferably, the pharmaceutical compositions of the present invention comprise amounts of the 5-HT3 receptor antagonist ondansetron and a selective dopamine D2 receptor antagonist, such as risperidone or olanzapine, that are sufficient to control a subject's obsessive, impulsive and compulsive behavioral activities. Kits comprising the combination of antagonists for the treatment of addictive disorders such as alcohol dependence are also provided.

Compositions and methods are provided that are useful for diagnosing, treating, and monitoring alcohol dependence and disorders, susceptibility to alcohol dependence disorders, as well as drug related dependence and disorders. The methods include treating patients with an antagonist of the serotonin receptor 5-HT3 for such disorders, wherein the patient's serotonin transporter gene SLC6A4 is known to have particular genotypes.

Compositions and methods are provided that are useful for diagnosing, treating, and monitoring alcohol dependence and disorders, susceptibility to alcohol dependence disorders, as well as drug related dependence and disorders. The methods include treating patients with an antagonist of the serotonin receptor 5-HT3 for such disorders, wherein the patient's serotonin transporter gene SLC6A4 is known to have particular genotypes.

The present invention provides compositions and methods useful for diagnosing, treating, and monitoring alcohol dependence and disorders and susceptibility to alcohol dependence disorders, as well as drug related dependence and disorders.

Pharmaceutical compositions are disclosed for the treatment of alcohol or cocaine dependence or addiction, alcohol dependence or addiction, reduction of alcohol withdrawal symptoms or aiding in the cessation or lessening of tobacco use or substance abuse or other behavioral dependencies. The pharmaceutical compositions are comprised of a therapeutically effective combination of a nicotinic receptor partial agonist and an alpha2delta ligand and a pharmaceutically acceptable carrier. The method of using these compounds is also disclosed.

The present invention relates to nalmefene for use in the treatment of anxiety disorders. The present invention further relates to nalmefene for use in the treatment of patients with alcohol dependence who have a co-morbid anxiety disorder. The invention further relates to nalmefene for use in the treatment of an anxiety disorder in said patients.

Gastric retentive dosage forms for sustained release of acamprosate are described which may allow once- or twice-daily dosing for both acute and long-term treatment of a disorder including alcohol dependence, tinnitus, sleep apnea, Parkinson's disease, levodopa-induced dyskinesias in Parkinson's disease, Alzheimer's disease, Huntington's disease, Amyotrophic lateral sclerosis, Cortical spreading depression, migraine, schizophrenia, anxiety, tardive dyskinesia, spasticity, multiple sclerosis, various types pain, or binge eating. Methods of treatment using the dosage forms and methods of making the dosage forms are also described.

The invention discloses a novel application of dihydromyricetin, namely an application of dihydromyricetin in preparation of food, health care products or medicines with a hangover alleviating effect.The dihydromyricetin has the advantages that the dihydromyricetin has a good hangover alleviating function, can be used for increasing the expression of hippocampus and neuronal GABAARs a4 subunits,has the effects of resisting alcoholism and alcohol dependence, can also effectively prevent liver reduced glutathione depletion and malondialdehyde increase caused by alcohol, reduces the content oftriglyceride, reduces the fatty degeneration degree of hepatocytes, and has good effects of preventing and treating alcoholic liver injury.

The invention relates to the technical field of relieving of alcohol dependence, and particularly relates to a fabrication method of anti-alcohol beverage. The anti-alcohol beverage containing aquilaria sinensis tea fungus gel is prepared by the following procedures: adding tea fungus to fresh aquilaria sinensis leaves and a turnjujube extracting solution and fermenting to prepare tea fungus liquid, and then adding gellan gum to prepare gel particles containing the tea fungus liquid; and adding fruit and vegetable juice prepared from tomato and sea-buckthorn juice and honey after bottling, and sealing. Sterile clean operation is realized in the fabrication process. By adopting the anti-alcohol beverage fabricated by the fabrication method, natural anti-alcohol beverage with significant effects of dispelling the effects of alcohol, quenching thirst, preventing or arresting vomiting, protecting gastric mucosa, and protecting the liver is provided for people.

The present invention relates to nalmefene for use in the reduction of alcohol consumption in a patient with alcohol dependence who has a high drinking risk level. The present invention also relates to nalmefene for use in the reduction of alcohol consumption in a patient with alcohol dependence who maintains a high DRL after an observation period following initial assessment.

The invention relates to the use of flumazenil in developing a drug used for the sequential administration of small quantities of flumazenil at short intervals, until a therapeutically effective quantity is administered to treat alcohol dependence.

The present invention provides pharmaceutical compositions for intranasal delivery of a benzodiazepine. The composition may contain a therapeutically effective amount of a benzodiazepine or a pharmaceutically acceptable salt thereof, and a permeation enhancer. The permeation enhancer may be propylene glycol or a Hsieh permeation enhancer. The present compositions have excellent bioavailability. After administration of the present compositions, therapeutically effective plasma levels of the benzodiazepine may be achieved rapidly. The present pharmaceutical composition may be used to treat a patient suffering from anxiety, epilepsy, insomnia, agitation, seizures, muscular disorders, alcohol dependence, and drug withdrawal.